Trimethoprim Sulfamethoxazole for Chronic Obstructive Pulmonary Disease Exacerbation Acute

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Chronic Obstructive Pulmonary Disease Exacerbation AcuteTrimethoprim Sulfamethoxazole - Drug
Eligibility
40 - 89
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether treating airway colonization with the fungus Pneumocystis jirovecii (PJ) will improve outcomes for patients with acute exacerbations of COPD.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
AIRVO 2; new asymmetric nasal cannula
2
Group 1: Rezafungin for Injection
1
Trimethoprim Sulfamethoxazole (TMP/SMX)

Study Objectives

2 Primary · 13 Secondary · Reporting Duration: up to 3 months

up to 3 months
Change in the COPD Assessment Test
Clearance of PJ from treated patients
Durability of Clearance of PJ from treated patients
Chronic Obstructive Airway Disease
Interval between exacerbations of COPD
Interval between hospital admissions
Length of stay for current AECOPD
Mortality
Need for mechanical ventilation
Need for medications to treat COPD
Number of hospital admissions (Total)
Number of hospital admissions (related to COPD)
Number of urgent care visits (Total)
Number of urgent care visits (related to COPD)
Time to return to baseline oxygen for the current AECOPD

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
AIRVO 2; new asymmetric nasal cannula
3
Group 1: Rezafungin for Injection
2
Trimethoprim Sulfamethoxazole (TMP/SMX)

Trial Design

2 Treatment Groups

TMP-SMX
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: Trimethoprim Sulfamethoxazole · Has Placebo Group · Phase 1 & 2

TMP-SMX
Drug
Experimental Group · 1 Intervention: Trimethoprim Sulfamethoxazole · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 months

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor
141 Previous Clinical Trials
114,406 Total Patients Enrolled
Matthew Sims, MD, PhDPrincipal InvestigatorWilliam Beaumont Hospitals
1 Previous Clinical Trials
20,614 Total Patients Enrolled

Eligibility Criteria

Age 40 - 89 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to produce a sputum sample.
AST and ALT ≤5x upper limit of normal.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top